Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

23 Dec 25

Views

130

Not Invested

Fair Value vs Share Price

€2.45

vs €0.963.1% undervalued

12.2%

Revenue growth

26.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Pharming Group

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with reasonable growth potential.

Market cap€640.3m

PB2.7x

Estimated Growth13.3%

Dividend YieldN/A

Full analysis

CEO & management

Fabrice Chouraqui

CEO

2.9yrs

CEO Tenure

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.